ES2168237T1 - Pirazolopirimidinas que actuan como antagonistas del receptor del crf. - Google Patents

Pirazolopirimidinas que actuan como antagonistas del receptor del crf.

Info

Publication number
ES2168237T1
ES2168237T1 ES97902295T ES97902295T ES2168237T1 ES 2168237 T1 ES2168237 T1 ES 2168237T1 ES 97902295 T ES97902295 T ES 97902295T ES 97902295 T ES97902295 T ES 97902295T ES 2168237 T1 ES2168237 T1 ES 2168237T1
Authority
ES
Spain
Prior art keywords
rent
crf
formula
hydroxial
cyclealkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES97902295T
Other languages
English (en)
Other versions
ES2168237T3 (es
Inventor
Chen-Neurocrine Bioscienc Chen
Thomas R-Neurocrine Biosc Webb
James R-Neurocrine Bi Mccarthy
Terence J-Neurocrine Bio Moran
Keith M-Neurocrine Bi Wilcoxen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Neurocrine Biosciences Inc
Original Assignee
Janssen Pharmaceutica NV
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Neurocrine Biosciences Inc filed Critical Janssen Pharmaceutica NV
Publication of ES2168237T1 publication Critical patent/ES2168237T1/es
Application granted granted Critical
Publication of ES2168237T3 publication Critical patent/ES2168237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), INCLUIDOS ESTEREOISOMEROS Y LAS FORMAS DE SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R 1 ES NR 4 R 5 U OR 5 ; R 2 ES ALQUILO C 1-6 , ALQUILOXI C 1-6 O ALQUILTIO C 1-6 ; R 3 ES HIDROGENO, ALQUILO C 1-6 , ALQUILSULFONILO C 1-6 , ALQUILSULFOXI C 1-6 O ALQUILTIO C 1-6 ; R 4 ES HIDR OGENO, ALQUILO C 1-6 , MONO - O DI(CICLOALQUIL C 36 ) METILO, CICLOALQUILO C 3-6 , ALQUENILO C 3-6 , HIDROXIALQUILO C 3-6 , ALQUILCARBONILOXI C 1-6 ALQUILO C SUB ,1-6 O ALQUILOXI C 1-6 ALQUILO C 1-6 ; R 5 ES ALQUILO C 1-8 , MONO - O DI(CICLOALQUIL C 3-6 )METILO, AR 1 CH 2 , ALQUILOXI C 1-6 ALQUILO C 1-6 , HIDROXIALQUILO C 1-6 , ALQUENILO C 3-6 , TIENILMETILO, FURANILMETILO, ALQUILTIO C 1-6 ALQUILO C 1-6 , MORFOLINILO, MONO - O DI(ALQUIL C 1-6 )AMINOALQUILO C 16 , D I(ALQUIL C 1-6 )AMINO, ALQUILCARBONIL C 1-6 ALQUILO C1-6 , ALQUILO C 1-6 SUSTITUIDO CON IMIDAZOLILO; O UN RADICAL DE LA FORMULA - ALK - O - CO - AR 1 ; O R 4 O R 5 TOMADOS JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS PUEDEN FORMAR UN GRUPO PIRROLIDINILO, PIPERIDINILO, HOMOPIPERIDINILO O MORFOLINILO OPCIONALMENTE SUSTITUIDO; QUE POSEEN PROPIEDADES ANTAGONISTICAS AL RECEPTOR DEL CRF; A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS COMO INGREDIENTES ACTIVOS; METODO PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA HIPERSECRECION DE CRF TALES COMO LA DEPRESION, ANSIEDAD, ABUSO DE SUSTANCIAS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE FORMULA (I).
ES97902295T 1996-02-07 1997-01-30 Pirazolopirimidinas como antagonistas de receptores de crf. Expired - Lifetime ES2168237T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1127996P 1996-02-07 1996-02-07
US11279 1996-02-07
US2768896P 1996-10-08 1996-10-08
US27688 1996-10-08

Publications (2)

Publication Number Publication Date
ES2168237T1 true ES2168237T1 (es) 2002-06-16
ES2168237T3 ES2168237T3 (es) 2007-04-01

Family

ID=26682204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97902295T Expired - Lifetime ES2168237T3 (es) 1996-02-07 1997-01-30 Pirazolopirimidinas como antagonistas de receptores de crf.

Country Status (27)

Country Link
EP (1) EP0880523B1 (es)
JP (2) JP3356291B2 (es)
KR (1) KR100421626B1 (es)
CN (1) CN1090189C (es)
AR (1) AR008577A1 (es)
AT (1) ATE336495T1 (es)
AU (1) AU713673B2 (es)
BG (1) BG102349A (es)
BR (1) BR9707391A (es)
CA (1) CA2233285C (es)
CZ (1) CZ244598A3 (es)
DE (2) DE880523T1 (es)
DK (1) DK0880523T3 (es)
EA (1) EA000803B1 (es)
EE (1) EE04282B1 (es)
ES (1) ES2168237T3 (es)
HU (1) HUP9900575A3 (es)
ID (1) ID15905A (es)
IL (1) IL123835A0 (es)
NO (1) NO310292B1 (es)
NZ (1) NZ330119A (es)
PL (1) PL191271B1 (es)
PT (1) PT880523E (es)
SK (1) SK106398A3 (es)
TR (1) TR199800792T2 (es)
TW (1) TW449599B (es)
WO (1) WO1997029109A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
HU229024B1 (en) * 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
NZ333727A (en) 1996-08-06 2000-09-29 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
AU6279598A (en) * 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6380203B1 (en) 1998-01-14 2002-04-30 Merck & Co., Inc. Angiogenesis inhibitors
PL200939B1 (pl) * 1998-01-28 2009-02-27 Bristol Myers Squibb Pharma Co Związki [1,5-a]-pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie tych związków
WO1999045007A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
EP1068205A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands
EP1149835A4 (en) * 1999-01-29 2002-08-21 Sumitomo Chemical Co AGENTS FOR INHIBITATION OF FAT
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
KR20040034594A (ko) * 2001-01-26 2004-04-28 브리스톨-마이어스스퀴브컴파니 코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
PL214231B1 (pl) * 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
US6872827B2 (en) 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
KR100984085B1 (ko) 2002-10-22 2010-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 7-페닐 피라졸로피리딘 화합물
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) * 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
EP1697369A1 (en) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
NZ547990A (en) * 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
JP2008503444A (ja) * 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
CN101115755B (zh) 2005-02-11 2013-01-16 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
PT1869049E (pt) * 2005-03-21 2009-05-26 Lilly Co Eli Compostos de imidazopiridazina
RU2412943C2 (ru) 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
WO2007017678A1 (en) * 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
CA2662000C (en) * 2006-09-20 2013-01-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
UA96458C2 (ru) * 2006-09-20 2011-11-10 Эли Лилли Энд Компани Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
PE20090506A1 (es) 2007-07-26 2009-05-28 Novartis Ag DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en) * 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
KR20250022913A (ko) 2017-08-14 2025-02-17 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
MX2019015318A (es) * 2017-08-14 2020-07-20 Spruce Biosciences Inc Antagonistas del receptor del factor liberador de corticotropina.
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN112423747A (zh) 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
MX2023001688A (es) 2020-08-12 2023-02-22 Spruce Biosciences Inc Metodos y composiciones para tratar el sindrome de ovario poliquistico.
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4211753Y1 (es) * 1964-06-06 1967-06-30
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
JPH0211753A (ja) * 1988-06-29 1990-01-16 Raimuzu:Kk ＴｉＡｌ系複合部材及びその製造方法
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
PL327284A1 (en) 1998-12-07
HUP9900575A3 (en) 2001-11-28
NO310292B1 (no) 2001-06-18
CN1090189C (zh) 2002-09-04
JP2002121194A (ja) 2002-04-23
CA2233285A1 (en) 1997-08-14
WO1997029109A1 (en) 1997-08-14
BG102349A (en) 1999-02-26
DE69736513T2 (de) 2007-04-05
DK0880523T3 (da) 2007-03-26
CN1205009A (zh) 1999-01-13
ATE336495T1 (de) 2006-09-15
IL123835A0 (en) 1998-10-30
EA199800394A1 (ru) 1998-10-29
HUP9900575A2 (hu) 1999-06-28
NZ330119A (en) 2000-02-28
AU1599197A (en) 1997-08-28
EP0880523B1 (en) 2006-08-16
NO981357D0 (no) 1998-03-25
DE880523T1 (de) 2002-07-04
AU713673B2 (en) 1999-12-09
EE04282B1 (et) 2004-04-15
DE69736513D1 (de) 2006-09-28
BR9707391A (pt) 1999-07-20
PL191271B1 (pl) 2006-04-28
PT880523E (pt) 2007-01-31
KR19990067391A (ko) 1999-08-16
ID15905A (id) 1997-08-14
KR100421626B1 (ko) 2004-05-20
TW449599B (en) 2001-08-11
NO981357L (no) 1998-08-03
CA2233285C (en) 2006-07-04
SK106398A3 (en) 1998-12-02
AR008577A1 (es) 2000-02-09
CZ244598A3 (cs) 1998-10-14
JP3356291B2 (ja) 2002-12-16
ES2168237T3 (es) 2007-04-01
EA000803B1 (ru) 2000-04-24
JP2000503661A (ja) 2000-03-28
EE9800124A (et) 1998-10-15
TR199800792T2 (xx) 1998-07-21
EP0880523A1 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
ES2167710T3 (es) Tiofenopirimidinas.
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
RU2434017C2 (ru) Миметики с обратной конфигурацией и относящиеся к ним способы
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
SV2002000696A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos pc9985ahxk/bb
EA200200417A1 (ru) Фармацевтически активные производные сульфонамида
ES2193391T3 (es) Antagonistas muscarinicos.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
ES2179353T3 (es) Antagonistas muscarinicos.
ES2158814A1 (es) Antagonistas iii del receptor ccr-3.
EA200300412A1 (ru) Фармацевтически активные производные сульфонамида, содержащие как липофильные, так и ионизируемые фрагменты, в качестве ингибиторов jun-протеинкиназ
ES2103289T3 (es) Derivados de pirimidina y composiciones herbicidas que los contienen.
GB0128499D0 (en) Therapeutic agents
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
YU33700A (sh) Kombinacija efikasna u tretiranju impotencije
EA200501041A1 (ru) Замещенные производные 1-пиперидин-4-ил-4-пирролидин-3-илпиперазина и их применение в качестве антагонистов нейрокининов
ES2172681T3 (es) Piramidinas y triazinas sustituidas con amino.
PA8466201A1 (es) Compuestos de indol 2,3-sustituidos como agentes antiinflamatorios y analgesicos
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
IL154964A0 (en) Benzsulfonamide derivatives, their preparation and pharmaceutical compositions containing them
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
AR013503A1 (es) Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion
AR032475A1 (es) Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende